Answers are grounded in this paper and cite their sources.
Background: While the standard first-line therapy for patients with advanced Non-Small-Cell Lung Cancer (NSCLC) without targetable genetic aberrations is platinum-based chemotherapy (CTX), recently, inhibitors of Programmed Cell Death-1 (PD-1) or its Legend (PD-L1) have set a novel option for such patients. To quantify the overall efficacy of those agents -here Called Checkpoint Inhibitors (CPIs) -and in patient subgroups, this meta-analysis was performed.
No takes yet. Share an insight, caveat, or question.
Em et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: